Leishmanicidal evaluation of tetrahydroprotoberberine and spirocyclic erythrina-alkaloids

Leishmaniasis is one of the World's most problematic diseases in developing countries. Traditional medicines to treat leishmaniasis have serious side effects, as well as significant parasite resistance problems. In this work, two alkaloids 1 and 2 were obtained from Corydalis govaniana Wall and...

Full description

Saved in:
Bibliographic Details
Published inMolecules (Basel, Switzerland) Vol. 19; no. 5; pp. 5692 - 5703
Main Authors Callejon, Daniel R, Riul, Thalita B, Feitosa, Luis G P, Guaratini, Thais, Silva, Denise B, Adhikari, Achyut, Shrestha, Ram L S, Marques, Lucas M M, Baruffi, Marcelo D, Lopes, João L C, Lopes, Norberto P
Format Journal Article
LanguageEnglish
Published Switzerland MDPI 05.05.2014
MDPI AG
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Leishmaniasis is one of the World's most problematic diseases in developing countries. Traditional medicines to treat leishmaniasis have serious side effects, as well as significant parasite resistance problems. In this work, two alkaloids 1 and 2 were obtained from Corydalis govaniana Wall and seven alkaloids 3-9, were obtained from Erythrina verna. The structures of the compounds were confirmed by mass spectrometry and 1D- and 2D-NMR spectroscopy. The leishmanicidal activity of compounds 1-9 against Leishmania amazonensis was tested on promastigote forms and cytotoxicity against J774 (macrophage cell line) was assessed in vitro. Compound 1 showed potent activity (IC50 = 0.18 µg/mL), compared with the standard amphotericin B (IC50 = 0.20 µg/mL). The spirocyclic erythrina-alkaloids showed lower leishmanicidal activity than dibenzoquinolizine type alkaloids.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules19055692